• Corpus ID: 22102314

Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.

@article{Mohammad1998SuccessfulTO,
  title={Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.},
  author={Ramzi M. Mohammad and Mary L. Varterasian and V P Almatchy and Ghadeer N. Hannoudi and George R. Pettit and Ayad Al-Katib},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1998},
  volume={4 5},
  pages={
          1337-43
        }
}
We tested the activity of dolastatin 10 (a natural product derived from the shell-less marine mollusk, Dolabella auricularia, a sea hare) and its structural modification, auristatin PE, alone and in combination with bryostatin 1 (a protein kinase C activator derived from the marine bryozoan Bugula neritina) on a human B-cell chronic lymphocytic leukemia cell line (WSU-CLL) and in a severe combined immune deficient (SCID) mouse xenograft model bearing this cell line. WSU-CLL cells were cultured… 

Figures and Tables from this paper

Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug.

  • PhilipZonder
  • Biology, Medicine
    Expert opinion on investigational drugs
  • 1999
There is ample in vitro data demonstrating that bryo 1 can sensitise tumour cells to cytotoxic agents, and recent clinical work has focused on combining b Bryo 1 with traditional chemotherapeutic agents for both haematologic and non-haematological cancers.

Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.

Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent in patients with hormone-refractory prostate cancer.

Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma 1

Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent in patients with hormone-refractory prostate cancer.

Marine natural products: Bryostatins in preclinical and clinical studies

Bryostatin's anticancer activity has been proved against various cancer types and their significant antineoplastic activity against several tumor types has also been established and described.

Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

Bryostatin-1 is a macrocyclic lactone derived from a marine invertebrate that binds to the regulatory domain of protein kinase C that inhibits proliferation, induces differentiation, and promotes apoptosis in numerous hematological and solid tumor cell lines.

Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells.

Progress in the development and acquisition of anticancer agents from marine sources.

Some of the technical strategies that are being employed to collect and identify novel marine products with potential antitumoral properties are reviewed, and a summary of the available clinical trial information of agents with promising activity is provided.

Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?

T cell therapy has a relatively strong scientific basis that justifies further clinical studies of immunotherapy in CLL and several studies have demonstrated that autologous T cells can recognize CLL cells.

Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB

The results suggest that CR011-vcMMAE may provide therapeutic benefit in malignant melanoma and that the antibody–drug conjugate produced complete regressions but the equivalent doses of free monomethylauristatin E or unconjugated antibody did not show anti-tumor effects.

TZT‐1027, an Antimicrotubule Agent, Attacks Tumor Vasculature and Induces Tumor Cell Death

TZT‐1027 quickly attacked the well‐developed vascular system of advanced tumors by a putative protein kinase‐dependent mechanism, and then blocked tumor blood flow, making it a potentially powerful tool for clinical cancer therapy.

References

SHOWING 1-10 OF 24 REFERENCES

Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.

It is recommended that Bryo1 be considered for clinical investigation in human B-cell tumors and might best be given combined with other chemotherapy agents used in the treatment of that disease.

Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.

The ability of bryostatin 1 to inhibit the in vitro growth and in vivo development of a panel of four murine tumors of diverse tissue origins and the observation that five of a Panel of six human B-cell lymphoma cell lines were sensitive to the growth inhibitory effects of bRYostatin in vitro suggest that brystatin may be effective in treating lymphoid malignancies in humans.

Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay

The history of antitumor drug discovery has essentially been the use of two lymphocytic leukemias of mice as selection funnels through which all agents needed to pass in order to advance toward clinical development, and it is thus not surprising that agents in the clinic are highly active against these tumor systems.

Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells.

The results suggest that bryostatin 1 activates HL-60 cell protein kinase C and that this effect is associated with induction of monocytic differentiation.

Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model.

The cell line and the xenograft described can be used as a model to facilitate the development of new therapeutic agents against CLL in man to test the efficacy of selected standard chemotherapy drugs and new therapeutic agent against WSU-CLL.

Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy.

  • S. GrantW. Jarvis
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1996
Although several of the principles established during this period continue to serve as guidelines for the development of modern chemotherapeutic regimens, it is uncertain whether this general strategy will prove superior to the more empirical approaches that preceded it.

CHEMOTHERAPY OF CHRONIC LYMPHOCYTIC LEUKEMIA.

The clinical use of chlorambucil in the treatment of chronic lymphocytic leukemia and malignant lymphomas was first reported in 1955 and a direct and concurrent comparison between the two drugs had not been made, so the Veterans Administration Cancer Chemotherapy Study Group decided to undertake such a study in 1960.